Who are inotropes therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Regular management+Levosimendan, Levosimendan Injection, epinephrine and levosimendan, Milrinone Lactate, low-dose dopamine + low-dose furosemide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inotropes-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

inotropes therapy — Competitive Intelligence Brief

inotropes therapy (inotropes therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inotropic agent. Area: Cardiovascular.

marketed Inotropic agent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

inotropes therapy (inotropes therapy) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Inotropes increase the force of cardiac muscle contraction to improve heart output in patients with reduced cardiac function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
inotropes therapy TARGET	inotropes therapy	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Inotropic agent
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container	Dobutamine Hydrochloride	Pfizer Inc.	marketed	Inotropic agent	Beta-receptors of the heart	1978-01-01
Regular management+Levosimendan	Regular management+Levosimendan	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / Inotropic agent	Cardiac troponin C
Levosimendan Injection	Levosimendan Injection	Peking University Third Hospital	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
epinephrine and levosimendan	epinephrine and levosimendan	Federal University of Juiz de Fora	marketed	Inotropic agent combination	Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C
Milrinone Lactate	Milrinone Lactate	Pfizer Inc.	marketed	Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator	Phosphodiesterase-3 (PDE-3) enzyme
low-dose dopamine + low-dose furosemide	low-dose dopamine + low-dose furosemide	Larissa University Hospital	marketed	Combination diuretic and inotropic agent	Dopamine-1 (DA1) receptor; Na-K-2Cl cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inotropic agent class)

Pfizer Inc. · 1 drug in this class
Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). inotropes therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/inotropes-therapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab